H. Wallerand

发表

Update on the medical treatment of metastatic renal cell carcinoma.

K. Bensalah, J. Patard, A. Ravaud, 2008, European urology.

Bladder cancer in patients after organ transplantation

A. Ravaud, H. Wallerand, J. Ferrière, 2010, Current opinion in urology.

[What is the clinical practice of partial nephrectomy in France?].

F. Guillé, J. Patard, A. Ravaud, 2008, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

Quelle pratique de la néphrectomie partielle en France

F. Guillé, J. Patard, A. Ravaud, 2008 .

[The role and method of fluorescence-guided cystoscopy in 2011 for management of bladder cancer: Review of the Oncology Committee of the French Urology Association].

H. Wallerand, G. Pignot, N. Houédé, 2011, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

[Management of non invasive bladder tumours (NMIBC)].

H. Wallerand, 2010, Bulletin du cancer.

[Intradiverticular bladder tumours: review of the Cancer Committee of the French Association of Urology].

H. Wallerand, G. Pignot, N. Houédé, 2012, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

Predictive risk factors for pain during extracorporeal shockwave lithotripsy.

H. Wallerand, G. Robert, J. Ferrière, 2009, Journal of endourology.

Embolization of Polycystic Kidneys as an Alternative to Nephrectomy Before Renal Transplantation: A Pilot Study

H. Wallerand, V. Pérot, J. Ferrière, 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Gefitinib Inhibits the Growth and Invasion of Urothelial Carcinoma Cell Lines in which Akt and MAPK Activation Is Dependent on Constitutive Epidermal Growth Factor Receptor Activation

H. Wallerand, D. Chopin, J. Thiery, 2006, Clinical Cancer Research.

Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population.

N. Rioux-Leclercq, J. Patard, H. Wallerand, 2011, European urology.

Therapeutic management of de novo urological malignancy in renal transplant recipients: the experience of the French Department of Urology and Kidney Transplantation from Bordeaux.

A. Ravaud, H. Wallerand, J. Bernhard, 2010, Urology.

The predictive value of muscularis mucosae invasion and p53 over expression on progression of stage T1 bladder carcinoma.

H. Wallerand, G. Adessi, C. Billerey, 2001, The Journal of urology.

Contrast-enhanced U.S.-guided biopsies following MRI in men with elevated PSA and previous negative biopsy.

A. Ravaud, H. Wallerand, J. Bernhard, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relationship between expansion of the CAG repeat in exon 1 of the androgen receptor gene and idiopathic male infertility.

H. Wallerand, G. Adessi, H. Bittard, 2001, Fertility and sterility.

Interpretation of Positive Flow Cytometric Crossmatch in the Era of the Single-Antigen Bead Assay

H. Wallerand, G. Robert, J. Moreau, 2011, Transplantation.

[Benefit of bladder and upper urinary tract urothelial tumors lymph node dissection: review from the Bladder Cancer Committee of the French National Association of Urology ("CC-AFU Vessie")].

H. Wallerand, H. Quintens, G. Pignot, 2012, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

Testicular‐sparing surgery for bilateral or monorchide testicular tumours: a multicenter study of long‐term oncological and functional results

H. Wallerand, J. Ferrière, J. Rigot, 2014, BJU international.

[Surgical treatment of metastatic urothelial carcinoma of the bladder: Review of the Cancer Committee of the French Association of Urology].

H. Wallerand, G. Pignot, N. Houédé, 2013, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

Oncologic Outcomes and Survival in pT0 Tumors After Radical Cystectomy in Patients Without Neoadjuvant Chemotherapy: Results from a Large Multicentre Collaborative Study

K. Bensalah, J. Patard, H. Wallerand, 2011, Annals of Surgical Oncology.

[Chemotherapy in early stage of hormone-resistant metastatic prostate cancer: what are the indications?].

H. Wallerand, N. Houédé, M. Rouprêt, 2010, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

[Postoperative radiotherapy of prostate cancer].

H. Wallerand, L. Salomon, N. Houédé, 2010, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines.

H. Wallerand, J. Thiery, F. Radvanyi, 2010, Urologic oncology.

Efficacy and tolerance of one‐third full dose bacillus Calmette–Guérin maintenance therapy every 3 months or 6 months: Two‐year results of URO‐BCG‐4 multicenter study

H. Wallerand, F. Saint, M. Colombel, 2015, International journal of urology : official journal of the Japanese Urological Association.

Sensitive allele-specific PCR assay able to detect FGFR3 mutations in tumors and urine from patients with urothelial cell carcinoma of the bladder.

H. Wallerand, D. Chopin, F. Radvanyi, 2005, Clinical chemistry.

[Bacillus Calmette-Guerin maintenance treatment in non-invasive bladder tumors: 1 year follow-up results of multicenter URO-BCG-4 trial].

H. Wallerand, F. Saint, M. Colombel, 2013, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

Case Report 2. Severe erythema multiforme induced by two consecutive anti-angiogenic drugs

A. Ravaud, H. Wallerand, T. Jouary, 2007 .

[Management of severe renal trauma].

H. Wallerand, H. Bittard, S. Bernardini, 2002, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

Predictive factors for ipsilateral recurrence after nephron-sparing surgery in renal cell carcinoma.

K. Bensalah, J. Patard, H. Wallerand, 2008, European urology.

[Conservative management of Corynebacterium urealyticum encrusted cystitis].

H. Wallerand, F. Kleinclauss, H. Bittard, 2006, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens.

H. Wallerand, D. Chopin, J. Thiery, 2004, Carcinogenesis.

[Benign urachus abnormalities: embryology, diagnosis and treatments].

H. Wallerand, J. Bernhard, G. Robert, 2008, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

N-Cadherin as a Novel Prognostic Marker of Progression in Superficial Urothelial Tumors

H. Wallerand, I. Lascombe, H. Bittard, 2006, Clinical Cancer Research.

Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signalling pathways

A. Ravaud, H. Wallerand, Robert R Reiter, 2008, Current opinion in urology.

The epithelial-mesenchymal transition-inducing factor TWIST is an attractive target in advanced and/or metastatic bladder and prostate cancers.

A. Ravaud, H. Wallerand, G. Robert, 2010, Urologic oncology.

Molecular Pathways in Metastatic Renal Cell Carcinoma: The Evolving Role of Mammalian Target of Rapamycin Inhibitors

A. Ravaud, H. Wallerand, 2009 .

Oncological risk of laparoscopic surgery in urothelial carcinomas

H. Wallerand, F. Saint, M. Rouprêt, 2009, World Journal of Urology.

[Treatment of infiltrating nonmetastatic bladder cancers in elderly patients].

H. Wallerand, F. Saint, M. Rouprêt, 2009, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

Protein kinase C signalling pathway is involved in the regulation of vascular endothelial growth factor expression in human bladder transitional carcinoma cells.

H. Wallerand, G. Adessi, H. Bittard, 2001, Cellular signalling.

INTENSIFIED METHOTREXATE, VINBLASTINE, DOXORUBICIN AND CISPLATIN (I-MVAC) WITH OR WITHOUT PANITUMUMAB AS FIRST-LINE TREATMENT OF ADVANCED UROTHELIAL CARCINOMA IN PATIENTS WITHOUT H-Ras NOR K-Ras MUTATIONS. RANDOMISED PHASE II STUDY

H. Wallerand, S. Culine, C. Bordeaux, 2012 .

Gallstone ileus: CT findings

H. Wallerand, É. Delabrousse, B. Bartholomot, 2009, European Radiology.

FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder.

H. Wallerand, D. Chopin, J. Thiery, 2003, Cancer research.

[Idiopathic male infertility and androgen receptors].

H. Wallerand, H. Bittard, É. Chabannes, 2001, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

The expression of Twist has an impact on survival in human bladder cancer and is influenced by the smoking status.

H. Wallerand, D. Chopin, J. Thiery, 2009, Urologic oncology.

Case study of the month. Complete histologic remission after sunitinib neoadjuvant therapy in T3b renal cell carcinoma.

A. Ravaud, H. Wallerand, J. Bernhard, 2009, European urology.

Laparoscopic radical prostatectomy in renal transplant recipients.

A. Ravaud, H. Wallerand, G. Robert, 2009, Urology.

Surgical Techniques in Urology aparoscopic Radical rostatectomy in Renal Transplant Recipients

H. Wallerand, J. Ferrière, P. Ballanger, 2022 .

[Simultaneous embolization of a large arteriovenous fistula and a renal pseudoaneurysm].

H. Wallerand, F. Kleinclauss, H. Bittard, 2006, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

Targeted therapies in non-muscle-invasive bladder cancer according to the signaling pathways.

A. Ravaud, H. Wallerand, S. Culine, 2011, Urologic oncology.

FGFR3 and TP53 gene mutations define distinct pathways at initial diagnosis in urothelial cell carcinomas of the bladder

H. Wallerand, D. Chopin, J. Thiery, 2003 .

Combination of Gemcitabine and Doxorubicin in Rapidly Progressive Metastatic Renal Cell Carcinoma and/or Sarcomatoid Renal Cell Carcinoma

A. Ravaud, H. Wallerand, G. Roubaud, 2011, Oncology.

Accuracy of FDG-PET/CT for Response Evaluation of Muscle-Invasive Bladder Cancer following Neoadjuvant or Induction Chemotherapy

H. Wallerand, O. Fitoussi, J. Riviere, 2023, Urologia Internationalis.

Salvage radiotherapy after high-intensity focussed ultrasound for recurrent localised prostate cancer.

H. Wallerand, J. Bernhard, A. Gelet, 2010, European urology.

[Checkup and management of upper urinary tract tumours in 2010: An update from the committee of cancer from the French National Association of Urology].

H. Wallerand, F. Saint, O. Traxer, 2010, Progrès en urologie (Paris).

[Recommendations Onco-Urology 2010: Urothelial tumors].

H. Wallerand, F. Saint, N. Houédé, 2010, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis

J. Rao, H. Wallerand, R. Figlin, 2006, British Journal of Cancer.

Renal failure with inguinoscrotal herniation of the bladder

H. Wallerand, G. Guichard, H. Bittard, 2003, BJU international.

ACCURACY OF ULTRASONOGRAPHY IN DIAGNOSIS OF TESTICULAR RUPTURE AFTER TESTICULAR TRAUMA

H. Wallerand, F. Kleinclauss, G. Guichard, 2006 .

[Primary angiosarcoma of the kidney: case report and literature review].

H. Wallerand, J. Bernhard, J. Ferrière, 2012, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

Tyrosine-kinase inhibitors in the treatment of muscle invasive bladder cancer and hormone refractory prostate cancer.

J. Patard, A. Ravaud, H. Wallerand, 2010, Archivos españoles de urología.

Predictive factors for ipsilateral recurrence after nephron-sparing surgery in renal cell carcinoma.

J. Patard, H. Wallerand, A. Belldegrun, 2008, European urology.

[Angiogenesis in bladder: prognosis indicator and therapeutic target].

H. Wallerand, H. Bittard, S. Bernardini, 2001, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.